Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Anlotinib in the Treatment of Recurrent Craniopharyngioma

NCT06970145 is registered in ClinicalTrials.gov with Nanfang Hospital, Southern Medical University as lead sponsor.

NCT NCT06970145
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06970145 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Anlotinib in the Treatment of Recurrent Craniopharyngioma
Lead sponsor
Nanfang Hospital, Southern Medical University
Phase
Phase 1/2
Overall status
Recruiting
Start date
April 25, 2025
Completion date
April 20, 2028
Enrollment
57 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

craniopharyngiomas